Question 1

Clinical Significance

Accepted Answer

Identifies eligibility for targeted therapies like Alpelisib. Provides precise genomic profiling of the tumor. Assists in personalizing treatment to improve survival rates.

Question 2

Target Groups

Accepted Answer

Patients with advanced or metastatic breast cancer. Hormone receptor-positive (HR+) cases. HER2-negative (HER2-) cases.

Question 3

Understanding Results

Accepted Answer

Positive Result: Indicates mutation presence, making targeted therapy a viable option. Negative Result: No mutation detected; alternative treatment protocols will be considered.

Key to Targeted Breast Cancer Therapy - PIK3CA Gene Mutation Testing for Breast Cancer